Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Colorado Anschutz

Sites in Aurora, CO

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 8:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1009
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Colorado Anschutz, Aurora, CO
Additional filters apply within this campus.

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

Filter and sort this campus

These controls apply only within University of Colorado Anschutz, Aurora, CO. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 565–576 of 1,009 matching trials with a site at University of Colorado Anschutz, Aurora, CO.
Indexed local directory records.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Stored official records

Recruiting Phase 3 Interventional

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

NCT06264180
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Melanoma
Interventions
Nivolumab, Nivolumab + Relatlimab, Pembrolizumab, Single-agent chemotherapy, Vusolimogene Oderparepvec
Biological · Drug
Lead sponsor
Replimune, Inc.
Industry
Eligibility
12 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
50
States / cities
Gilbert, Arizona • La Jolla, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 30, 2026, 8:18 PM EDT
Recruiting Phase 3 Interventional

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

NCT06592924
Status at this site: Recruiting
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma)
Interventions
ADT, Abiraterone, Apalutamide, Darolutamide (BAY 1841788), Docetaxel, Enzalutamide
Drug
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
18 Years and older · Male only
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
374
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 272 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 1, 2026, 8:18 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

NCT05533697
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Ipilimumab, Nivolumab, Pembrolizumab, mRNA-4359
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
12 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 27, 2026, 10:00 AM EDT
Recruiting Not applicable Interventional

Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure

NCT06526988
Status at this site: Recruiting
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
EPIC-HF Patient-facing Tool, PROMPT-HF Clinician-facing Alert
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Walnut Creek, California • Aurora, Colorado • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 13, 2026, 11:42 PM EDT
Recruiting Phase 2 Interventional

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

NCT05887609
Status at this site: Recruiting
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovary Cancer, Peritoneal Cancer
Interventions
Mirvetuximab Soravtansine-gynx, Olaparib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
6
States / cities
Irvine, California • Aurora, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 7, 2026, 12:10 PM EDT
Recruiting No phase listed Observational

The Intersection of Oncology Care and Worker Well-Being

NCT05250284
Status at this site: Recruiting
View directory record Official record
Conditions
Solid Tumor
Interventions
PROMIS, WellBQ
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 70 Years · Male only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 30, 2026, 2:59 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

NCT05726864
Site status not listed — check the official record
View directory record Official record
Conditions
Colorectal Cancer, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D, NRAS G12C, NRAS G12D, NRAS G12R, NRAS G12S, NRAS G12V, Pancreatic Ductal Adenocarcinoma
Interventions
ELI-002 7P
Drug
Lead sponsor
Elicio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
28
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 13, 2026, 4:35 PM EDT
Active, not recruiting Phase 2 Interventional

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

NCT05458674
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
Interventions
Eribulin, Trastuzumab, Tucatinib
Drug
Lead sponsor
Criterium, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Albuquerque, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Jul 29, 2026, 11:17 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

NCT04452591
Site status not listed — check the official record
View directory record Official record
Conditions
High-grade Ta/ T1 Papillary Disease Bladder Cancer, Non Muscle Invasive Bladder Cancer
Interventions
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside
Biological · Other
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
45
States / cities
Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 9, 2026, 8:06 PM EDT
Active, not recruiting Not applicable Interventional

Study in Parkinson Disease of Exercise

NCT04284436
Site status not listed — check the official record
View directory record Official record
Conditions
Parkinson Disease
Interventions
Treadmill walking
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 80 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
24
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 14, 2026, 8:58 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Clinical Trial Multi-analyte Blood Test

NCT03694600
Site status not listed — check the official record
View directory record Official record
Conditions
Liver Cirrhosis
Interventions
Multi-analyte blood Test
Diagnostic Test
Lead sponsor
Helio Genomics
Industry
Eligibility
21 Years to 84 Years
Enrollment
1,900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
38
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Aug 1, 2026, 6:32 AM EDT
Recruiting Phase 1 Interventional

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

NCT05098613
Status at this site: Recruiting
View directory record Official record
Conditions
B-cell Non-Hodgkin Lymphoma (B-NHL), CNS Lymphoma, Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma
Interventions
CD19x22 CAR T Cells
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
16 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 13, 2026, 10:54 PM EDT

About this University of Colorado Anschutz institution page

What this page lists
ClinicalTrials.gov records that list University of Colorado Anschutz in Aurora, CO as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.